Display options
Cite
Immohr MB, Eschlböck SM, Rellecke P, et al. The quality of afterlife: surviving extracorporeal life support after therapy-refractory circulatory failure-a comprehensive follow-up analysis. ESC Heart Fail. 2021;8(6):4968-4975doi: 10.1002/ehf2.13554.
Immohr, M. B., Eschlböck, S. M., Rellecke, P., Dalyanoglu, H., Tudorache, I., Boeken, U., Akhyari, P., Albert, A., Lichtenberg, A., & Aubin, H. (2021). The quality of afterlife: surviving extracorporeal life support after therapy-refractory circulatory failure-a comprehensive follow-up analysis. ESC heart failure, 8(6), 4968-4975. https://doi.org/10.1002/ehf2.13554
Immohr, Moritz Benjamin, et al. "The quality of afterlife: surviving extracorporeal life support after therapy-refractory circulatory failure-a comprehensive follow-up analysis." ESC heart failure vol. 8,6 (2021): 4968-4975. doi: https://doi.org/10.1002/ehf2.13554
Immohr MB, Eschlböck SM, Rellecke P, Dalyanoglu H, Tudorache I, Boeken U, Akhyari P, Albert A, Lichtenberg A, Aubin H. The quality of afterlife: surviving extracorporeal life support after therapy-refractory circulatory failure-a comprehensive follow-up analysis. ESC Heart Fail. 2021 Dec;8(6):4968-4975. doi: 10.1002/ehf2.13554. Epub 2021 Sep 04. PMID: 34480427; PMCID: PMC8712909.
Copy Download .nbib Format: NLM
Share it on

ESC Heart Fail. 2021 Dec;8(6):4968-4975. doi: 10.1002/ehf2.13554. Epub 2021 Sep 04.

The quality of afterlife: surviving extracorporeal life support after therapy-refractory circulatory failure-a comprehensive follow-up analysis.

ESC heart failure

Moritz Benjamin Immohr, Sophie Margaretha Eschlböck, Philipp Rellecke, Hannan Dalyanoglu, Igor Tudorache, Udo Boeken, Payam Akhyari, Alexander Albert, Artur Lichtenberg, Hug Aubin

Affiliations

  1. Department of Cardiac Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, Düsseldorf, 40225, Germany.
  2. Department of Cardiac Surgery, Städtisches Krankenhaus Dortmund, Dortmund, Germany.

PMID: 34480427 PMCID: PMC8712909 DOI: 10.1002/ehf2.13554

Abstract

AIMS: Extracorporeal life support (ECLS) represents a popular treatment option for therapy-refractory circulatory failure and substantially increases survival. However, comprehensive follow-up (FU) data beyond short-term survival are mostly lacking. Here, we analyse functional recovery and quality of life of longer-term survivors.

METHODS AND RESULTS: Between 2011 and 2016, a total of n = 246 consecutive patients were treated with ECLS for therapy-refractory circulatory failure in our centre. Out of those, 99 patients (40.2%) survived the first 30 days and were retrospectively analysed. Fifty-eight patients (23.6%) were still alive after a mean FU of 32.4 ± 16.8 months. All surviving patients were invited to a prospective, comprehensive clinical FU assessment, which was completed by 39 patients (67.2% of survivors). Despite high incidence of early functional impairments, FU assessment revealed a high degree of organ and functional recovery with more than 70% of patients presenting with New York Heart Association class ≤ II, 100% free of haemodialysis, 100% free of moderate or severe neurological disability, 71.8% free of moderate or severe depression, and 84.4% of patients reporting to be caring for themselves without need for assistance.

CONCLUSIONS: Patients surviving the first 30 days of ECLS therapy for circulatory failure without severe adverse events have a quite favourable outcome in terms of subsequent survival as well as functional recovery, showing the potential of ECLS therapy for patients to recover. Patients can recover even after long periods of mechanically support and regain physical and mental health to participate in their former daily life and work.

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Keywords: Cardiocirculatory failure; Cardiogenic shock; ECLS; ECMO; Outcome; Quality of life

References

  1. Eur Heart J. 2015 Sep 1;36(33):2246-56 - PubMed
  2. Thorac Cardiovasc Surg. 2020 Aug;68(5):417-424 - PubMed
  3. Eur Heart J. 2016 Jul 14;37(27):2129-2200 - PubMed
  4. Interact Cardiovasc Thorac Surg. 2021 Apr 19;32(4):607-615 - PubMed
  5. Crit Care Med. 2008 May;36(5):1404-11 - PubMed
  6. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2769-78 - PubMed
  7. Circulation. 2017 Oct 17;136(16):e232-e268 - PubMed
  8. JACC Heart Fail. 2020 Nov;8(11):892-902 - PubMed
  9. Intensive Care Med. 2017 Jun;43(6):855-866 - PubMed
  10. Eur J Cardiothorac Surg. 2016 Mar;49(3):802-9 - PubMed
  11. Qual Life Res. 2016 Nov;25(11):2787-2798 - PubMed
  12. J Intensive Care Med. 2016 Jun;31(5):319-24 - PubMed
  13. Resuscitation. 2017 Dec;121:151-157 - PubMed
  14. Circ Res. 2014 Apr 25;114(9):1453-68 - PubMed
  15. Anesthesiology. 2018 Sep;129(3):406-416 - PubMed
  16. Intensive Care Med. 2016 Mar;42(3):370-378 - PubMed
  17. J Card Fail. 2007 Oct;13(8):643-8 - PubMed
  18. Anesth Analg. 2019 Apr;128(4):772-780 - PubMed
  19. ESC Heart Fail. 2021 Dec;8(6):4968-4975 - PubMed
  20. Curr Opin Support Palliat Care. 2010 Dec;4(4):233-7 - PubMed
  21. Perfusion. 2015 May;30(4):284-90 - PubMed
  22. Curr Opin Support Palliat Care. 2007 Dec;1(4):260-6 - PubMed
  23. J Am Coll Cardiol. 2017 Nov 14;70(20):2476-2486 - PubMed
  24. Eur J Cardiothorac Surg. 2019 Feb 1;55(2):238-246 - PubMed
  25. J Am Geriatr Soc. 2005 Apr;53(4):695-9 - PubMed
  26. ASAIO J. 2017 Jan/Feb;63(1):60-67 - PubMed
  27. Nat Rev Nephrol. 2016 Oct;12(10):610-23 - PubMed
  28. EuroIntervention. 2016 Mar;11(12):1363-71 - PubMed
  29. JACC Heart Fail. 2016 Sep;4(9):698-708 - PubMed

Publication Types